KCT0005370招募中未知
Production of SARS-CoV-2 antigen specific cytotoxic T lymphocytes
The Catholic University of Korea, Seoul St. Mary's Hospital0 个研究点目标入组 10 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 65(Year)（—）
- 性别
- All
入选标准
- •For COVID-19 treated individuals:
- •1. Those who consent to the study
- •2. Aged 20 - to 65 years old
- •3. Individual who has been diagnosed with COVID-19 and released from quarantine, that is, the person who meets all the criteria for public release by the CDC:
- •A. (clinical standard): no fever and no clinical symptoms
- •B. (diagnostic criteria) PCR test results are negative twice every 24 hours
- •For health donors:
- •1. Those who consent
- •2. Aged 20 to 65 years old
- •3. Those who do not have any fever or respiratory symptoms
- •4. Negative for Anti-SARS-CoV-2 Ab IgG antibodies
排除标准
- •1. Those who do not consent
- •2. Those under 20 or over 65 years of age
- •3. Positive for Anti-SARS-CoV-2 IgG antibodies
- •4. Positive for HIV, syphilis or hepatitis B and C carriers.
- •5. Those with any active infections requiring systemic medical treatment
- •6. Those who have been diagnosed with any other serious diseases
研究者
相似试验
招募中
不适用
Production of clinical-grade SARS-CoV-2 antigen specific cytotoxic T lymphocytesKCT0005864The Catholic University of Korea, Seoul St. Mary's Hospital100
已完成
不适用
ongitudinal serological study of SARS-CoV-2 positive individuals07.1DRKS00028057KH Labor GmbH165
招募中
1 期
Phase I clinical trial of Osvid-19 inactivated vaccine for Covid-19 (Osve Pharmaceutical Company)COVID-19 disease.COVID-19, virus identifiedU07.1IRCT20210622051670N1Osve pharmaceutical company40
进行中（未招募）
1 期
Generation of SARS-CoV-2-specific T lymphocytes from recovered donors and administration to high-risk COVID-19 patientsCOVID-19 high-risk patientsEUCTR2021-001022-22-GRGe???? ??s???µe?? Tessa??????? Ge?????? ?apa????????182
进行中（未招募）
1 期
SARS-CoV-2 immune responseimmune response to COVDI-19 vaccinationEUCTR2021-001202-30-NLDiakonessenhuis400